The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Targeting JAK2 V617F in MPNs with interferon alpha and arsenic trioxide
From the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the combination of interferon and arsenic trioxide to target JAK2 V617F in myeloproliferative neoplasms (MPNs). Promising preclinical results have been seen, showing specific and synergistric targeting of the mutation.
